Coronary angioplasty in the patient with acute myocardial infarction

Charles Landau, D. Brent Glamann, John E. Willard, L. David Hillis, Richard A. Lange

Research output: Contribution to journalArticle

Abstract

In patients with acute myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) may be used (1) to restore antegrade flow in the infarct artery (so called "primary" PTCA) instead of thrombolytic therapy, (2) to establish antegrade coronary flow after unsuccessful thrombolytic therapy (so called "rescue" or "salvage" PTCA), and (3) to reduce the residual infarct artery stenosis after successful thrombolysis. This review examines the prospective, randomized studies that have addressed the use of PTCA for each of these purposes. In selected circumstances, PTCA is a reasonable alternative to thrombolytic therapy in patients with evolving or recent Q-wave myocardial infarction. In those patients with acute myocardial infarction complicated by cardiogenic shock, PTCA may be the preferred treatment. After thrombolytic therapy, the use of PTCA in the absence of spontaneous or provocable ischemia offers no benefit with regard to left ventricular function or survival. In this circumstance, its use is associated with an excessive risk of bleeding, transfusions, and emergent coronary artery bypass surgery when performed within hours of infarction.

Original languageEnglish (US)
Pages (from-to)536-543
Number of pages8
JournalAmerican Journal of Medicine
Volume96
Issue number6
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Coronary Balloon Angioplasty
Angioplasty
Myocardial Infarction
Thrombolytic Therapy
Arteries
Cardiogenic Shock
Left Ventricular Function
Coronary Artery Bypass
Infarction
Pathologic Constriction
Ischemia
Prospective Studies
Hemorrhage
Survival

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Landau, C., Glamann, D. B., Willard, J. E., Hillis, L. D., & Lange, R. A. (1994). Coronary angioplasty in the patient with acute myocardial infarction. American Journal of Medicine, 96(6), 536-543. https://doi.org/10.1016/0002-9343(94)90094-9

Coronary angioplasty in the patient with acute myocardial infarction. / Landau, Charles; Glamann, D. Brent; Willard, John E.; Hillis, L. David; Lange, Richard A.

In: American Journal of Medicine, Vol. 96, No. 6, 1994, p. 536-543.

Research output: Contribution to journalArticle

Landau, C, Glamann, DB, Willard, JE, Hillis, LD & Lange, RA 1994, 'Coronary angioplasty in the patient with acute myocardial infarction', American Journal of Medicine, vol. 96, no. 6, pp. 536-543. https://doi.org/10.1016/0002-9343(94)90094-9
Landau, Charles ; Glamann, D. Brent ; Willard, John E. ; Hillis, L. David ; Lange, Richard A. / Coronary angioplasty in the patient with acute myocardial infarction. In: American Journal of Medicine. 1994 ; Vol. 96, No. 6. pp. 536-543.
@article{1f64db5acd0742aba010ba6c3fa7b6aa,
title = "Coronary angioplasty in the patient with acute myocardial infarction",
abstract = "In patients with acute myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) may be used (1) to restore antegrade flow in the infarct artery (so called {"}primary{"} PTCA) instead of thrombolytic therapy, (2) to establish antegrade coronary flow after unsuccessful thrombolytic therapy (so called {"}rescue{"} or {"}salvage{"} PTCA), and (3) to reduce the residual infarct artery stenosis after successful thrombolysis. This review examines the prospective, randomized studies that have addressed the use of PTCA for each of these purposes. In selected circumstances, PTCA is a reasonable alternative to thrombolytic therapy in patients with evolving or recent Q-wave myocardial infarction. In those patients with acute myocardial infarction complicated by cardiogenic shock, PTCA may be the preferred treatment. After thrombolytic therapy, the use of PTCA in the absence of spontaneous or provocable ischemia offers no benefit with regard to left ventricular function or survival. In this circumstance, its use is associated with an excessive risk of bleeding, transfusions, and emergent coronary artery bypass surgery when performed within hours of infarction.",
author = "Charles Landau and Glamann, {D. Brent} and Willard, {John E.} and Hillis, {L. David} and Lange, {Richard A.}",
year = "1994",
doi = "10.1016/0002-9343(94)90094-9",
language = "English (US)",
volume = "96",
pages = "536--543",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Coronary angioplasty in the patient with acute myocardial infarction

AU - Landau, Charles

AU - Glamann, D. Brent

AU - Willard, John E.

AU - Hillis, L. David

AU - Lange, Richard A.

PY - 1994

Y1 - 1994

N2 - In patients with acute myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) may be used (1) to restore antegrade flow in the infarct artery (so called "primary" PTCA) instead of thrombolytic therapy, (2) to establish antegrade coronary flow after unsuccessful thrombolytic therapy (so called "rescue" or "salvage" PTCA), and (3) to reduce the residual infarct artery stenosis after successful thrombolysis. This review examines the prospective, randomized studies that have addressed the use of PTCA for each of these purposes. In selected circumstances, PTCA is a reasonable alternative to thrombolytic therapy in patients with evolving or recent Q-wave myocardial infarction. In those patients with acute myocardial infarction complicated by cardiogenic shock, PTCA may be the preferred treatment. After thrombolytic therapy, the use of PTCA in the absence of spontaneous or provocable ischemia offers no benefit with regard to left ventricular function or survival. In this circumstance, its use is associated with an excessive risk of bleeding, transfusions, and emergent coronary artery bypass surgery when performed within hours of infarction.

AB - In patients with acute myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) may be used (1) to restore antegrade flow in the infarct artery (so called "primary" PTCA) instead of thrombolytic therapy, (2) to establish antegrade coronary flow after unsuccessful thrombolytic therapy (so called "rescue" or "salvage" PTCA), and (3) to reduce the residual infarct artery stenosis after successful thrombolysis. This review examines the prospective, randomized studies that have addressed the use of PTCA for each of these purposes. In selected circumstances, PTCA is a reasonable alternative to thrombolytic therapy in patients with evolving or recent Q-wave myocardial infarction. In those patients with acute myocardial infarction complicated by cardiogenic shock, PTCA may be the preferred treatment. After thrombolytic therapy, the use of PTCA in the absence of spontaneous or provocable ischemia offers no benefit with regard to left ventricular function or survival. In this circumstance, its use is associated with an excessive risk of bleeding, transfusions, and emergent coronary artery bypass surgery when performed within hours of infarction.

UR - http://www.scopus.com/inward/record.url?scp=0028283944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028283944&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(94)90094-9

DO - 10.1016/0002-9343(94)90094-9

M3 - Article

C2 - 8017452

AN - SCOPUS:0028283944

VL - 96

SP - 536

EP - 543

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 6

ER -